Insight, China's Pharmaceutical Industry

Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations

Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that China’s National Medical Products Administration (NMPA) has...

Company Drug

Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate

Fineline Cube Apr 30, 2026

Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that China’s regulatory authorities have granted Breakthrough Therapy...

Company

Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength

Fineline Cube Apr 30, 2026

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported first quarter 2026 financial results with revenues increasing 19%...

Company Drug

Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026

Fineline Cube Apr 30, 2026

Gilead Sciences, Inc. (NASDAQ: GILD) announced that the U.S. Food and Drug Administration (FDA) has...

Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has assumed exclusive licensing rights from...

Company Medical Device

Suzhou Basecare Medical Secures China’s First NMPA Approval for Thalassemia Preimplantation Genetic Testing Kit

Fineline Cube Apr 30, 2026

Suzhou Basecare Medical Co., Ltd. (HKG: 2170) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

HutchMed’s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia

Fineline Cube Apr 30, 2026

HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced that China’s National Medical Products Administration (NMPA)...

Company

Novartis Q1 2026 Results Show Strong Brand Momentum Offset by Generic Erosion; FY Guidance Reaffirmed

Fineline Cube Apr 29, 2026

Novartis AG (NYSE: NVS) reported Q1 2026 financial results showing USD 13.1 billion in net...

Company

Astellas Reports Strong FY2025 Results with 12% Revenue Growth Driven by Oncology Portfolio Expansion

Fineline Cube Apr 29, 2026

Astellas Pharma Inc. (TYO: 4503) reported FY2025 financial results showing JPY 2,139.2 billion (USD 13.9...

Company

Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement

Fineline Cube Apr 29, 2026

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) reported Q1 2026 financial results...

Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026

Fosun Pharma (SHA: 600196; HKG: 2196) announced it has signed a Memorandum of Cooperation with...

Company Drug

Changchun High & New Tech’s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial

Fineline Cube Apr 29, 2026

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its GenSci161 has...

Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced a strategic partnership with Sun...

Company Medical Device

Abbott Secures FDA Clearance and CE Mark for Ultreon 3.0 AI-Powered OCT Imaging Platform

Fineline Cube Apr 29, 2026

Abbott (NYSE: ABT) announced it has received U.S. Food and Drug Administration (FDA) clearance and...

Company Deals

Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801

Fineline Cube Apr 29, 2026

Vivacta Biotechnology, a Shanghai-based in vivo chimeric antigen receptor (CAR)-T therapy developer, announced the successful...

Company Drug

Insilico Medicine Secures Chinese Clinical Clearance for AI-Discovered Rentosertib Inhalation in Pulmonary Fibrosis

Fineline Cube Apr 29, 2026

Insilico Medicine (HKG: 3696), a generative artificial intelligence (AI)-driven biotechnology company, announced it has received...

Company

Mindray Reports Mixed Q1 2026 Results with Strong International Growth Offset by Domestic Weakness

Fineline Cube Apr 29, 2026

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) reported Q1 2026 financial results showing RMB...

Company Drug

Immunotech Biopharm’s EAL Cellular Therapy Rejected by NMPA; Confirmatory Trials Required

Fineline Cube Apr 29, 2026

Immunotech Biopharm Ltd. (HKG: 6978), a chimeric antigen receptor T-cell (CAR-T) specialist based in China,...

Company Drug

GluBio Pharmaceutical Advances GLB-002 Molecular Glue Degrader to Phase II for Relapsed Follicular Lymphoma

Fineline Cube Apr 29, 2026

GluBio Pharmaceutical Co., Ltd., a molecular glue targeted protein degradation (TPD) specialist based in Zhejiang,...

Company Drug

Henlius Biotech Secures European Commission Approval for Poherdy Biosimilar to Roche’s Perjeta

Fineline Cube Apr 29, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced it has received marketing authorization from the European...

Insight, China's Pharmaceutical Industry

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Cellular Intelligence Acquires Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy Program, Plans AI-Driven Acceleration

BeOne Medicines’ BCL2 Inhibitor Beqalzi (Sonrotoclax) Receives FDA Fast Track for Relapsed Mantle Cell Lymphoma – 52% Response Rate in Phase I/II Study

Zhongsheng Pharma’s Onradivir (Anruiwei) Receives NMPA Review Acceptance for Pediatric Influenza A Indication – Phase III Data Shows Favorable Efficacy vs. Tamiflu

Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations

Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate

Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength

Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Suzhou Basecare Medical Secures China’s First NMPA Approval for Thalassemia Preimplantation Genetic Testing Kit

HutchMed’s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia

Novartis Q1 2026 Results Show Strong Brand Momentum Offset by Generic Erosion; FY Guidance Reaffirmed

Astellas Reports Strong FY2025 Results with 12% Revenue Growth Driven by Oncology Portfolio Expansion

Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Changchun High & New Tech’s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Abbott Secures FDA Clearance and CE Mark for Ultreon 3.0 AI-Powered OCT Imaging Platform

Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801

Insilico Medicine Secures Chinese Clinical Clearance for AI-Discovered Rentosertib Inhalation in Pulmonary Fibrosis

Mindray Reports Mixed Q1 2026 Results with Strong International Growth Offset by Domestic Weakness

Immunotech Biopharm’s EAL Cellular Therapy Rejected by NMPA; Confirmatory Trials Required

GluBio Pharmaceutical Advances GLB-002 Molecular Glue Degrader to Phase II for Relapsed Follicular Lymphoma

Henlius Biotech Secures European Commission Approval for Poherdy Biosimilar to Roche’s Perjeta

You Missed

BeOne Medicines’ BCL2 Inhibitor Beqalzi (Sonrotoclax) Receives FDA Fast Track for Relapsed Mantle Cell Lymphoma – 52% Response Rate in Phase I/II Study

China’s NHSA Unveils Five-Year Medical Insurance Fund Supervision Plan (2026–2030) – AI-Powered Oversight to Combat Fraud Across Healthcare Ecosystem

Zhongsheng Pharma’s Onradivir (Anruiwei) Receives NMPA Review Acceptance for Pediatric Influenza A Indication – Phase III Data Shows Favorable Efficacy vs. Tamiflu

Huadong Medicine Receives NMPA Approval for HDM2017 ADC Trial in Colorectal Cancer – Cadherin 17-Targeting Therapy Shows Broad Solid Tumor Potential